MedsEngine LLC, a provider of chronic disease management software, presented its findings on blood pressure control to the European Society of Hypertension in Milan, Italy, May 23-26, 2025. The findings showed that users of the MedsEngine Hypertension module were able to achieve high BP control rates, to a goal of <140/90, in less than two office visits.
Health Technology Insights: Southwest Michigan Dermatology Chooses NextGen Healthcare
“Hypertension control in less than 2 office visits for 10 consecutive years”
These results build on earlier presentations at the European Society of Cardiology Congress in 2023 and 2024, where MedsEngine reported sustained blood pressure control rates of 92% over a 10-year period. Further analysis linked these outcomes to a significant reduction in heart attacks and cerebrovascular events, underscoring the long-term clinical impact of optimized hypertension management.
The MedsEngine platform enables physicians and advanced practice providers to rapidly evaluate patients and generate personalized, evidence-based medication recommendations in just minutes—transforming the standard of care for hypertension.
Health Technology Insights: Omada Health Announces Launch of Initial Public Offering
“Our data from over 14,000 patients across two major medical groups show that personalized, technology-driven medication recommendations dramatically reduce the risk of strokes and heart attacks and improve patient understanding and adherence,” said Dr. Doug Romer, Chief Medical Officer at MedsEngine. “This level of precision and efficiency illustrates the value of using technology to control chronic diseases.”
Health Technology Insights: Jeff Jochims Appointed Executive Chair at Genesee Scientific
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
